CT Evaluation of the Myocardial Effects of Risk Factors

DESCRIPTION (provided by applicant): The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that include obesity, insulin resistance, dyslipidemia, and hypertension, and is characterized by substantial inflammation. The increase in cardiovascular morbidity and mortality due to MetS precedes development of occlusive vascular lesions, and may conceivably be linked to direct impact on the myocardial microcirculation. Understanding the mechanisms by which MetS affects the heart would facilitate development of strategies for monitoring and management of target organ injury in MetS, but the nature and mechanisms of the cardiac effects of MetS have not been fully elucidated. Importantly, however, novel imaging techniques for studying the myocardial microcirculation, and swine models that mimic human cardiovascular physiology and pathophysiology, now provide a unique opportunity to serially assess the effects of MetS on myocardial microvascular function and structure. The hypothesis underlying this proposal is that MetS elicits myocardial microvascular rarefaction and remodeling, which are partly mediated by inflammation through monocyte chemoattractant protein-1 (MCP-1), and that consequent microvascular loss interferes with compensatory mechanisms meant to protect the heart from ischemic insults. To test this hypothesis we will utilize obese swine, a unique large animal model with a naturally occurring constellation of features of the MetS, and a combination of powerful imaging techniques both in vivo and in vitro. Multi-detector computed tomography (CT) will be used to quantify non-invasively myocardial regional perfusion, ischemia, and microvascular integrity, in conjunction with blood oxygen level- dependent magnetic resonance imaging assessment of myocardial oxygenation in response to increased cardiac demand. Micro-CT will then be used to reconstruct myocardial microvessels in situ, and assess their permeability and myocardial lipid accumulation. Furthermore, chronic blockade of MCP-1 will establish the role of inflammation and MCP-1 as a central mechanism underlying the cardiac effects of MetS. Three Specific Aims will implement powerful and novel tools to test the following hypotheses: 1). MetS exacerbates myocardial microvascular dysfunction and loss by inducing myocardial inflammation, oxidative stress, and altered growth factor expression; 2). Micro-vascular rarefaction and remodeling are functionally consequential and exacerbate myocardial ischemia during ischemic insult (like chronic coronary artery obstruction), but would be improved by a change of diet or administration of vascular endothelial growth factor; 3). Inflammation and MCP-1 contribute to microvascular alterations induced by MetS. Elucidation of the mechanisms involved in early deleterious effects of MetS at the level of the myocardial microcirculation would advance our understanding of the pathogenesis of cardiac injury during the evolution of MetS, in a manner potentially applicable to humans. Indeed, these studies may shed light into and have a substantial ramification for designing preventive and diagnostic measures for management of MetS patients.